Gelteq (GELS) Competitors $1.33 +0.05 (+3.91%) As of 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock GELS vs. COEP, IPSC, ANVS, KLRS, NBRV, GRCE, LTRN, FGEN, ATHE, and JSPRShould you be buying Gelteq stock or one of its competitors? The main competitors of Gelteq include Coeptis Therapeutics (COEP), Century Therapeutics (IPSC), Annovis Bio (ANVS), Kalaris Therapeutics (KLRS), Nabriva Therapeutics (NBRV), Grace Therapeutics (GRCE), Lantern Pharma (LTRN), FibroGen (FGEN), Alterity Therapeutics (ATHE), and Jasper Therapeutics (JSPR). These companies are all part of the "pharmaceutical products" industry. Gelteq vs. Its Competitors Coeptis Therapeutics Century Therapeutics Annovis Bio Kalaris Therapeutics Nabriva Therapeutics Grace Therapeutics Lantern Pharma FibroGen Alterity Therapeutics Jasper Therapeutics Coeptis Therapeutics (NASDAQ:COEP) and Gelteq (NASDAQ:GELS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations. Do institutionals and insiders believe in COEP or GELS? 13.9% of Coeptis Therapeutics shares are held by institutional investors. 24.3% of Coeptis Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is COEP or GELS more profitable? Gelteq's return on equity of 0.00% beat Coeptis Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Coeptis TherapeuticsN/A -201.73% -108.46% Gelteq N/A N/A N/A Which has stronger earnings & valuation, COEP or GELS? Gelteq has lower revenue, but higher earnings than Coeptis Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoeptis Therapeutics$263.56K243.60-$10.88M-$5.80-2.30Gelteq$100K125.55-$2.33MN/AN/A Does the media favor COEP or GELS? In the previous week, Coeptis Therapeutics and Coeptis Therapeutics both had 2 articles in the media. Coeptis Therapeutics' average media sentiment score of 1.91 beat Gelteq's score of 0.93 indicating that Coeptis Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coeptis Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Gelteq 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryCoeptis Therapeutics beats Gelteq on 5 of the 8 factors compared between the two stocks. Get Gelteq News Delivered to You Automatically Sign up to receive the latest news and ratings for GELS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GELS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GELS vs. The Competition Export to ExcelMetricGelteqMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.56M$3.09B$5.74B$9.78BDividend YieldN/A2.26%4.40%4.04%P/E RatioN/A21.2230.8326.39Price / Sales125.55206.90382.9086.63Price / CashN/A44.2437.7259.11Price / Book1.028.0710.106.62Net Income-$2.33M-$54.08M$3.26B$265.42M7 Day Performance-0.75%3.94%3.90%3.58%1 Month Performance-30.37%3.02%3.73%0.46%1 Year PerformanceN/A6.84%37.68%19.41% Gelteq Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GELSGelteqN/A$1.33+3.9%N/AN/A$12.56M$100K0.00N/ACOEPCoeptis Therapeutics0.7752 of 5 stars$13.43-1.3%N/A+218.2%$47.14MN/A-2.322Positive NewsIPSCCentury Therapeutics3.0244 of 5 stars$0.54-0.7%$3.75+593.0%-74.8%$46.75M$6.59M-1.87170ANVSAnnovis Bio2.3554 of 5 stars$2.38-4.4%$18.00+656.3%-74.7%$46.39MN/A-1.173KLRSKalaris Therapeutics0.3954 of 5 stars$2.46-4.3%$3.00+22.0%N/A$46.00MN/A0.00110NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070GRCEGrace Therapeutics2.5688 of 5 stars$3.28+0.3%$12.00+265.9%N/A$45.36MN/A-3.81N/ANews CoverageHigh Trading VolumeLTRNLantern Pharma2.6596 of 5 stars$4.19-6.3%$25.00+496.7%-5.4%$45.25MN/A-2.3520FGENFibroGen4.7309 of 5 stars$11.09+4.4%$43.00+287.7%+4.8%$44.80M$29.62M-29.18570Positive NewsATHEAlterity Therapeutics2.6253 of 5 stars$5.02-0.2%$12.00+139.0%+271.7%$44.53MN/A0.0010News CoveragePositive NewsGap UpJSPRJasper Therapeutics2.8705 of 5 stars$2.95+3.5%$28.75+874.6%-85.4%$44.31MN/A-0.4920 Related Companies and Tools Related Companies Coeptis Therapeutics Competitors Century Therapeutics Competitors Annovis Bio Competitors Kalaris Therapeutics Competitors Nabriva Therapeutics Competitors Grace Therapeutics Competitors Lantern Pharma Competitors FibroGen Competitors Alterity Therapeutics Competitors Jasper Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GELS) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gelteq Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Gelteq With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access